SAN FRANCISCO--(BUSINESS WIRE)--VIA Pharmaceuticals, Inc., a privately-held drug development company headquartered in San Francisco, California, today announced that it has named Richard L. Anderson, Mark N.K. Bagnall and David T. Howard as VIA’s remaining nominees to be appointed as directors of the combined company effective upon the closing of the merger transaction between VIA and Corautus Genetics Inc. (Nasdaq: VEGF). The closing of the merger is conditioned upon, among other matters, approval of the merger by Corautus’s stockholders.
